(Q38781734)

6 September 2017

title

Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease (English)

1 reference

6 September 2017

Davide Corti

1

1 reference

6 September 2017

Jeffrey D Kearns

series ordinal

2

1 reference

6 September 2017

publication date

17 March 2016

1 reference

Current Opinion in Immunology

6 September 2017

published in

1 reference

6 September 2017

volume

40

1 reference

6 September 2017

page(s)

51-61

1 reference

Concepts in solid tumor evolution

6 September 2017

cites work

1 reference

12 December 2020

Generation of stable cell clones expressing mixtures of human antibodies

1 reference

12 December 2020

Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma

1 reference

12 December 2020

Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials

1 reference

12 December 2020

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

1 reference

12 December 2020

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

1 reference

12 December 2020

Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies

1 reference

12 December 2020

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

1 reference

12 December 2020

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

1 reference

12 December 2020

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

1 reference

12 December 2020

A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.

1 reference

12 December 2020

Alternative molecular formats and therapeutic applications for bispecific antibodies

1 reference

12 December 2020

Combination vaccines: development, clinical research and approval

1 reference

12 December 2020

Anti-infective monoclonals step in where antimicrobials fail

1 reference

12 December 2020

Toxin B is essential for virulence of Clostridium difficile

1 reference

12 December 2020

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

1 reference

12 December 2020

Intratumor heterogeneity: evolution through space and time

1 reference

12 December 2020

Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology

1 reference

12 December 2020

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis

1 reference

12 December 2020

Passive antibody therapy for infectious diseases

1 reference

12 December 2020

Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs

1 reference

12 December 2020

Liquid biopsy: monitoring cancer-genetics in the blood

1 reference

12 December 2020

A comprehensive catalogue of somatic mutations from a human cancer genome

1 reference

12 December 2020

Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications

1 reference

12 December 2020

First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity

1 reference

12 December 2020

Antibody protection against botulinum neurotoxin intoxication in mice

1 reference

12 December 2020

Liquid biopsies: genotyping circulating tumor DNA

1 reference

12 December 2020

Cancer genome landscapes

1 reference

12 December 2020

Emerging antibody combinations in oncology

1 reference

12 December 2020

Single-batch production of recombinant human polyclonal antibodies

1 reference

12 December 2020

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

1 reference

12 December 2020

A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis

1 reference

12 December 2020

Recombinant polyclonal antibodies for cancer therapy

1 reference

12 December 2020

The coming of age of engineered multivalent antibodies.

1 reference

12 December 2020

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

12 December 2020

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

1 reference

12 December 2020

Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis

1 reference

12 December 2020

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

1 reference

12 December 2020

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

1 reference

12 December 2020

Monoclonal antibody-based therapies for microbial diseases

1 reference

12 December 2020

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters

1 reference

12 December 2020

Back to the future: recombinant polyclonal antibody therapeutics

1 reference

12 December 2020

Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

1 reference

12 December 2020

Oligoclonal antibodies to target the ErbB family

1 reference

12 December 2020

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

1 reference

12 December 2020

Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity

1 reference

12 December 2020

Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies

1 reference

12 December 2020

Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia.

1 reference

12 December 2020

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

1 reference

12 December 2020

Combination products regulation at the FDA

1 reference

12 December 2020

Advances in the production and downstream processing of antibodies

1 reference

12 December 2020

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

1 reference

12 December 2020

1 reference

12 December 2020

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation

1 reference

12 December 2020

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

1 reference

12 December 2020

Detection of circulating tumor DNA in early- and late-stage human malignancies

1 reference

12 December 2020

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

1 reference

12 December 2020

The use of combinations of monoclonal antibodies in clinical oncology

1 reference

12 December 2020

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

1 reference

12 December 2020

Building better monoclonal antibody-based therapeutics.

1 reference

12 December 2020

Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models

1 reference

12 December 2020

Broadly neutralizing antiviral antibodies

1 reference

12 December 2020

Translational implications of tumor heterogeneity

1 reference

12 December 2020

Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts

1 reference

12 December 2020

Treatment with monoclonal antibodies against Clostridium difficile toxins

1 reference

12 December 2020

Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases

1 reference

12 December 2020

Species-Specific Chromosome Engineering Greatly Improves Fully Human Polyclonal Antibody Production Profile in Cattle

1 reference

12 December 2020

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies

1 reference

12 December 2020

Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

1 reference

12 December 2020

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.

1 reference

12 December 2020

Combination cancer immunotherapy and new immunomodulatory targets

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Cloned transchromosomic calves producing human immunoglobulin

1 reference

12 December 2020

[The mechanism of diphtheria immunity and tetanus immunity in animals. 1890].

1 reference

12 December 2020

Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor

1 reference

12 December 2020

Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.

1 reference

12 December 2020

Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.

1 reference

12 December 2020

Targeting the ERBB family in cancer: couples therapy

1 reference

12 December 2020

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

1 reference

12 December 2020

Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A.

1 reference

12 December 2020

Tumor cell plasticity: the challenge to catch a moving target

1 reference

12 December 2020

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa

1 reference

12 December 2020

Antibody therapy of cancer

1 reference

12 December 2020

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

1 reference

12 December 2020

Antimicrobial peptides: their physicochemical properties and therapeutic application

1 reference

12 December 2020

Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies.

1 reference

12 December 2020

Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect

1 reference

12 December 2020

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

1 reference

12 December 2020

A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study

1 reference

12 December 2020

Gastrointestinal cancer: Tracking tumour evolution through liquid biopsy

1 reference

12 December 2020

Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody

1 reference

12 December 2020

Capturing the natural diversity of the human antibody response against vaccinia virus

1 reference

12 December 2020

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

1 reference

12 December 2020

Quantification of heterogeneity as a biomarker in tumor imaging: a systematic review

1 reference

12 December 2020

Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers

1 reference

12 December 2020

Antibodies to watch in 2015

1 reference

12 December 2020

Industrialization of mAb production technology: the bioprocessing industry at a crossroads

1 reference

12 December 2020

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

1 reference

12 December 2020

Restoring the balance: immunotherapeutic combinations for autoimmune disease

1 reference

12 December 2020

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer

1 reference

12 December 2020

The road to resistance: EGFR mutation and cetuximab.

1 reference

12 December 2020

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance

1 reference

12 December 2020

Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer

1 reference

12 December 2020

10.1016/J.COI.2016.03.001

Identifiers

DOI

1 reference

6 September 2017

0 references

1 reference